D. Slamon, G. Clark, S. Wong, W. Levin, A. Ullrich et al., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, vol.235, issue.4785, pp.177-182, 1987.
DOI : 10.1126/science.3798106

D. Slamon, W. Godolphin, L. Jones, J. Holt, S. Wong et al., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, vol.244, issue.4905, pp.707-712, 1989.
DOI : 10.1126/science.2470152

R. Nicholson, R. Mcclelland, J. Gee, D. Manning, P. Cannon et al., Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapy, Breast Cancer Research and Treatment, vol.53, issue.1, pp.117-125, 1994.
DOI : 10.1007/BF00666187

. Ladjemi, 13:R17 http://breast-cancer-research.com/content, Breast Cancer Research, vol.131, p.17, 2011.

M. Martin, A. Rodriguez-lescure, A. Ruiz, E. Alba, L. Calvo et al., Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer, JNCI Journal of the National Cancer Institute, vol.100, issue.11, pp.805-814, 2008.
DOI : 10.1093/jnci/djn151

M. Disis, K. Schiffman, L. Salazar, B. Almand, and K. Knutson, HER-2/neu vaccines, Cancer Chemother Biol Response Modif, vol.21, issue.2, pp.275-285, 2003.
DOI : 10.1016/S0921-4410(03)21013-9

M. Disis, E. Calenoff, G. Mclaughlin, A. Murphy, W. Chen et al., Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer, Cancer Res, vol.54, pp.16-20, 1994.

G. Peoples, P. Goedegebuure, R. Smith, D. Linehan, I. Yoshino et al., Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide., Proceedings of the National Academy of Sciences, vol.92, issue.2, pp.432-436, 1995.
DOI : 10.1073/pnas.92.2.432

N. Nanda and E. Sercarz, Induction of anti-self-immunity to cure cancer, Cell, vol.82, issue.1, pp.13-17, 1995.
DOI : 10.1016/0092-8674(95)90047-0

M. Disis, T. Gooley, K. Rinn, D. Davis, M. Piepkorn et al., Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide???Based Vaccines, Journal of Clinical Oncology, vol.20, issue.11, pp.2624-2632, 2002.
DOI : 10.1200/JCO.2002.06.171

E. Mittendorf, C. Storrer, C. Shriver, S. Ponniah, and G. Peoples, Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptides, Breast Cancer Research and Treatment, vol.266, issue.1, pp.85-93, 2005.
DOI : 10.1007/s10549-005-0988-1

A. Roth, F. Rohrbach, R. Weth, B. Frisch, F. Schuber et al., Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct, British Journal of Cancer, vol.40, issue.8, pp.1421-1429, 2005.
DOI : 10.1007/s00262-003-0468-6

P. Lollini, D. Giovanni, C. Pannellini, T. Cavallo, F. Forni et al., Cancer immunoprevention, Future Oncology, vol.60, issue.1, pp.57-66, 2005.
DOI : 10.1002/ijc.11092

A. Gritzapis, L. Mahaira, S. Perez, N. Cacoullos, M. Papamichail et al., Vaccination with Human HER-2/neu (435-443) CTL Peptide Induces Effective Antitumor Immunity against HER-2/neu-Expressing Tumor Cells In vivo, Cancer Research, vol.66, issue.10, pp.5452-5460, 2006.
DOI : 10.1158/0008-5472.CAN-05-4018

G. Peoples, J. Holmes, M. Hueman, E. Mittendorf, A. Amin et al., Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02, Clinical Cancer Research, vol.14, issue.3, pp.797-803, 2008.
DOI : 10.1158/1078-0432.CCR-07-1448

N. Jerne, Towards a network theory of the immune system, Ann Immunol, vol.125, pp.373-389, 1974.

K. Foon, W. John, M. Chakraborty, R. Das, A. Teitelbaum et al., Clinical and Immune Responses in Resected Colon Cancer Patients Treated With Anti-Idiotype Monoclonal Antibody Vaccine That Mimics the Carcinoembryonic Antigen, Journal of Clinical Oncology, vol.17, issue.9, pp.2889-2895, 1999.
DOI : 10.1200/JCO.1999.17.9.2889

S. Reinartz, S. Kohler, H. Schlebusch, K. Krista, P. Giffels et al., Vaccination of Patients with Advanced Ovarian Carcinoma with the Anti-Idiotype ACA125: Immunological Response and Survival (Phase Ib/II), Clinical Cancer Research, vol.10, issue.5, pp.1580-1587, 2004.
DOI : 10.1158/1078-0432.CCR-03-0056

P. Sabbatini, J. Dupont, C. Aghajanian, F. Derosa, E. Poynor et al., Phase I Study of Abagovomab in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Clinical Cancer Research, vol.12, issue.18, pp.5503-5510, 2006.
DOI : 10.1158/1078-0432.CCR-05-2670

K. Foon, J. Lutzky, R. Baral, J. Yannelli, L. Hutchins et al., Clinical and Immune Responses in Advanced Melanoma Patients Immunized With an Anti-Idiotype Antibody Mimicking Disialoganglioside GD2, Journal of Clinical Oncology, vol.18, issue.2, pp.376-384, 2000.
DOI : 10.1200/JCO.2000.18.2.376

D. Cerio, A. Zabalegui, N. Rodriguez-calvillo, M. Inoges, S. Bendandi et al., Anti-idiotype antibodies in cancer treatment, Oncogene, vol.3, issue.25, pp.3594-3602, 2007.
DOI : 10.1016/S1471-4914(01)02126-8

M. Coelho, P. Gauthier, M. Pugniere, F. Roquet, and A. Pelegrin, Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice, British Journal of Cancer, vol.12, issue.10, pp.2032-2041, 2004.
DOI : 10.1038/sj.bjc.6601825

D. Finkle, Z. Quan, V. Asghari, J. Kloss, N. Ghaboosi et al., HER2-Targeted Therapy Reduces Incidence and Progression of Midlife Mammary Tumors in Female Murine Mammary Tumor Virus huHER2-Transgenic Mice, Clinical Cancer Research, vol.10, issue.7, pp.2499-2511, 2004.
DOI : 10.1158/1078-0432.CCR-03-0448

G. Curigliano, G. Spitaleri, M. Dettori, M. Locatelli, E. Scarano et al., Vaccine immunotherapy in breast cancer treatment: promising, but still early, Expert Review of Anticancer Therapy, vol.7, issue.9, pp.1225-1241, 2007.
DOI : 10.1586/14737140.7.9.1225

M. Cuello, S. Ettenberg, A. Clark, M. Keane, R. Posner et al., Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2, Cancer Res, vol.61, pp.4892-4900, 2001.

F. Felici, A. Luzzago, A. Folgori, and C. R. , Mimicking of discontinuous epitopes by phage-displayed peptides, II. Selection of clones recognized by a protective monoclonal antibody against the Bordetella pertussis toxin from phage peptide libraries, Gene, vol.128, issue.1, pp.21-27, 1993.
DOI : 10.1016/0378-1119(93)90148-V

H. Cho, K. Mason, K. Ramyar, A. Stanley, S. Gabelli et al., Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab, Nature, vol.24, issue.6924, pp.756-760, 2003.
DOI : 10.1038/nature01392

H. Geysen, S. Rodda, and T. Mason, A priori delineation of a peptide which mimics a discontinuous antigenic determinant, Molecular Immunology, vol.23, issue.7, pp.709-715, 1986.
DOI : 10.1016/0161-5890(86)90081-7

A. Riemer, M. Klinger, S. Wagner, A. Bernhaus, L. Mazzucchelli et al., Generation of Peptide Mimics of the Epitope Recognized by Trastuzumab on the Oncogenic Protein Her-2/neu, The Journal of Immunology, vol.173, issue.1, pp.394-401, 2004.
DOI : 10.4049/jimmunol.173.1.394

A. Riemer, G. Kraml, O. Scheiner, C. Zielinski, and E. Jensen-jarolim, Matching of trastuzumab (Herceptin??) epitope mimics onto the surface of Her-2/neu ??? a new method of epitope definition, Molecular Immunology, vol.42, issue.9, pp.1121-1124, 2005.
DOI : 10.1016/j.molimm.2004.11.003

A. Kosmaczewska, L. Ciszak, S. Potoczek, and I. Frydecka, The significance of Treg cells in defective tumor immunity, Archivum Immunologiae et Therapiae Experimentalis, vol.56, issue.3, pp.181-191, 2008.
DOI : 10.1007/s00005-008-0018-1

S. Crone, Y. Zhao, L. Fan, Y. Gu, S. Minamisawa et al., ErbB2 is essential in the prevention of dilated cardiomyopathy, Nature Medicine, vol.94, issue.5, pp.459-465, 2002.
DOI : 10.1074/JBC.273.2.1252

D. Slamon, L. , B. Shak, S. Fuchs, H. Paton et al., Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2, New England Journal of Medicine, vol.344, issue.11, pp.783-792, 2001.
DOI : 10.1056/NEJM200103153441101

G. Curigliano, G. Spitaleri, E. Pietri, M. Rescigno, F. De-braud et al., Breast cancer vaccines: a clinical reality or fairy tale? Ann Oncol, pp.750-762, 2006.
DOI : 10.1093/annonc/mdj083

URL : http://annonc.oxfordjournals.org/cgi/content/short/17/5/750